Recent Advances in Prodrug Approach over Conventional Drug Therapy

Prodrugs and Targeted Delivery

With the continuous development of the pharmaceutical industry, people have always paid attention to the safety and effectiveness of drugs, including innovative drugs and generic drugs. For pharmaceutical companies as manufacturers, drug development is a very lengthy process that requires high costs, millions of man-hours, thousands of trials, and the mobilization of hundreds of researchers. Therefore, efforts need to be made to develop drugs with high safety and effectiveness. Drug research and development plays an important role today. Based on this, this article applied computer molecular simulation embedded technology and artificial intelligence technology to drug research and development. First, the problems faced in the research and development of anti-inflammatory disease-dependent tumor drugs were introduced, and then the applications of computer molecular simulation embedded technology and artificial intelligence technology in drug research and development were analyzed. Subsequently, the application of artificial intelligence in drug research and development teaching was analyzed, and a teaching system based on computer molecular simulation embedded technology and artificial intelligence was designed. Finally, the application effects of computer molecular simulation embedded technology and artificial intelligence technology were analyzed, and a feasible conclusion was drawn. The use of computer molecular simulation embedded technology and artificial intelligence technology can greatly improve the efficiency of drug research and development, and the research and development safety of imatinib mesylate has been improved by 7%. On the other hand, it can improve students' learning interest and stimulate their learning interest, and students' drug research and development capabilities have been improved. Drug research and development for inflammatory-dependent tumors has good application prospects.

Prodrug approach: An overview of recent cases

Food Effect on Oral Bioavailability: Old and New Questions.

Setting the stage Drug research relies on classical scienti!c methods and statistical inferences across the spectrum of preclinical discovery to clinical practice: formulate a hypothesis, test the hypothesis experimentally, analyze the data, and make informed decisions to accept, reject, or re!ne the hypothesis. Drug discovery and development is iterative, collaborative, and multidisciplinary, culminating in pivotal clinical trials that provide evidence of ecacy and safety to support market access. Through the mid-1990s, this process worked remarkably well in some disease areas with the rapid identi!cation of validated drug targets, such as with antiretroviral drugs for treating HIV and statins for managing high cholesterol in cardiovascular diseases, leading to the launch of many new medicines that reduced morbidity and mortality and increased life expectancy. But in other diseases, such as cancer, progress has been more modest. Over the past 15 years, this success story has been threatened by expiring patents, poorly understood disease mechanisms, a high rate of attrition, and burgeoning drug development costs. As a result, the pace of new medicines coming out of the pharmaceutical industry pipelines has slowed considerably. Translational bioinformatics (TBI) has recently emerged as an important technology to address these challenges. At the risk of being oversold, TBI is expected to help bridge the gap between pathogenic pathways and disease phenotypes and guide molecular measurements that can improve target identi!cation, drug selection, and clinical trial design. #e quotation by Einstein above emphasizes the importance of “thinking about thinking” and the need to better understand human cognition. In the context of scienti!c thinking, cognition is the thought process that describes how data acquired from drug research are transformed into information and stored as knowledge for future decision making. In today’s world of rapid technological and computational advances, it is easy to get lost in the ubiquitous and dicult problem of cognitive overload and workload timelines. TBI is a novel approach to solving these problems and is designed to avoid getting “lost in the data.” It can help decision makers answer important questions by integrating pertinent information beyond that which could be achieved by human memory, intuition, and pattern thinking alone. Today, pharmaceutical companies, academia, and others involved in drug discovery and development have access to a far more sophisticated understanding of disease pathways and biological networks to decode complex clinical disease phenotypes. #is has changed the way drug research is conducted. It also has led to recent breakthroughs in targeted therapies for cancer such as vemurafenib, a B-Raf enzyme inhibitor for the treatment of late-stage melanoma, and crizotinib, an anaplastic lymphoma kinase inhibitor for treating some types of non–small cell lung carcinomas. Federal agencies have become part of the solution to problems in drug discovery and development. #e US Food and Drug Administration (FDA) had taken notice of the trend toward lower productivity when it launched the Critical Path Initiative in 2004, which was intended to frame a national strategy for driving innovation in scienti!c tools and processes that would foster a turnaround in the success of drug development. More recently, the FDA published a strategic plan for advancing regulatory science and emphasized the importance of TBI in several priority areas and implementation strategies.1 #e Obama administration started a government drug development center, called the National Center for Advancing Translational Sciences, to partner with pharmaceutical companies and other organizations to apply scienti!c advances and develop new tools for drug research. Both initiatives acknowledge the rapid growth of biomedical knowledge and the urgent need for new predictive bioinformatics tools in drug discovery, development, and postmarketing clinical practice. This article provides a macroscopic view of TBI and a perspective on the future of knowledge development in the drug discovery, development, regulatory, and clinical practice continuum.

Phase I trials in oncology: a new era has started

Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development

Low water solubility and low bioavailability are frequent problems in drug development, particularly in the area of central nervous system (CNS) drugs. This short review describes selected prodrug approaches which have been developed to enhance the bioavailability of drugs, especially that of poorly soluble drugs. Some of the most successful drugs on the market are prodrugs. With a better understanding of active-transport processes at cell membranes in the gut as well as at the blood-brain barrier, the importance of prodrug approaches will further increase in the future. Prodrug approaches will already be considered in the early phase of drug discovery.

Chapter 1 - Nanocarriers in drug delivery: Classification, properties, and targeted drug delivery applications

Targeting drugs or pharmaceutical compounds to tumor site increases cancer treatment efficiency and therapeutic outcome. Nanoparticles are unique delivery systems for site-targeting within an organism. Many novel technologies have been established in drug research and development area. Nanotechnology now offers nanometer size polymeric nanoparticles and these particles direct drugs to their targets, protect drugs against degradation, and release the drug in a controlled manner. Modification of nanoparticle surface by molecules leads to prolonged retention and accumulation in the target area of the organism. Current efforts of designing polymeric nanoparticles include drug activation in the target area, controlled drug release at the site upon stimulation, and increased drug loading capacity of drug polymer conjugates. Recent progress in molecular mechanism elucidation of cancer cell and rising research in nanoparticle designs may provide efficient cancer treatment modality and innovative nanoparticle designs in the near future. Recent years have seen many developments in the field of innovative peptide based drug nanoparticles. Although none of them approved to be used in clinics yet, peptides are promising structures due to their simple and nonantigenic nature. Biodegradable materials are also preferred materials in drug delivery. Polysaccharide-based micelle systems improve hydrophobic drug and protein delivery. Ease of saccharide structure modification improves pharmacokinetic and pharmacodynamic properties of drug molecules as well as their delivery to a specific site in a controlled manner and sustained rate. Small molecules, especially drugs, conjugated to nanoparticles and several nanoparticles of this type are in the clinical trials and at the market. This review provides recent developments of polymeric nanoparticles conjugated with peptides, saccharides, and small molecules in cancer theraphy.

Insoluble drug delivery strategies: review of recent advances and business prospects

The research and development of new traditional Chinese medicine drugs has gradually formed a new system based on the combination of traditional Chinese medicine theory, human experience, and clinical trials(referred to as the "three combinations"). However, given the characteristics of traditional Chinese medicine's "syndrome differentiation and treatment" and "diverse components and complex mechanisms", there are still problems in the current research and development of new traditional Chinese medicine drugs, such as insufficient research on the material basis and overall mechanism of action, and incomplete evidence chain system. At the same time, there are still many challenges in collecting human experience, evaluating clinical efficacy, and controlling the quality of active ingredients, which restrict the innovation process of research and development of new traditional Chinese medicine drugs. Network pharmacology, based on the core theory of "network targets", breaks through the limitations of the traditional "single target" reduction analysis research model, emphasizing the comprehensive effects of disease or syndrome biological networks as targets to characterize the overall regulatory mechanism of traditional Chinese medicine prescriptions. This is in line with the idea of the holistic view of traditional Chinese medicine, providing a new method consistent with the holistic view of traditional Chinese medicine for studying the complex mechanism of action of traditional Chinese medicine and the development of new traditional Chinese medicine drugs. It is internationally recognized as a "next generation of drug research model". In order to promote the research of new tools, methods, and standards for the evaluation of traditional Chinese medicine, and to break through the fundamental, critical, and cutting-edge technical challenges in the field of traditional Chinese medicine regulation, this consensus aims to explore the characteristics, progress, challenges, applicable paths, and specific application situations of network pharmacology as a new theory, method, and tool applied to the research and development of new traditional Chinese medicine drugs, in order to improve the quality of research and development of new traditional Chinese medicine drugs and accelerate the efficiency of research and development of new traditional Chinese medicine products.

Does neurology need a faster FDA?

The incidence rate of nervous system diseases has increased in recent years. Nerve injury or neurodegenerative diseases usually cause neuronal loss and neuronal circuit damage, which seriously affect motor nerve and autonomic nervous function. Therefore, safe and effective treatment is needed. As traditional drug research becomes slower and more expensive, it is vital to enlist the help of cutting-edge technology. Virtual screening (VS) is an attractive option for the identification and development of promising new compounds with high efficiency and low cost. With the assistance of computer-aided drug design (CADD), VS is becoming more and more popular in new drug development and research. In recent years, it has become a reality to transform non-neuronal cells into functional neurons through small molecular compounds, which provides a broader application prospect than transcription factor-mediated neuronal reprogramming. This review mainly summarizes related theory and technology of VS and the drug research and development using VS technology in nervous system diseases in recent years, and focuses more on the potential application of VS technology in neuronal reprogramming, thus facilitating new drug design for both prevention and treatment of nervous system diseases.

Europe to boost development of new antimicrobial drugs